Hurlow Wealth Management Group’s AbbVie ABBV Stock Holding History

Hurlow Wealth Management Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.03M	Buy	4,076 +52	+1%	+$11.2K	0.21%	41
2026 Q1	$875K	Buy	4,024 +3	+0.1%	+$665	0.21%	41
2025 Q4	$919K	Sell	4,021 -130	-3%	-$29.6K	0.22%	41
2025 Q3	$961K	Sell	4,151 -1,380	-25%	-$281K	0.25%	40
2025 Q2	$1.03M	Hold	5,531	–	–	0.29%	37
2025 Q1	$1.16M	Hold	5,531	–	–	0.36%	38
2024 Q4	$983K	Buy	5,531 +48	+0.9%	+$8.82K	0.31%	39
2024 Q3	$1.08M	Buy	5,483 +2	+0%	+$373	0.34%	38
2024 Q2	$940K	Sell	5,481 -5	-0.1%	-$828	0.32%	39
2024 Q1	$999K	Buy	5,486 +2	+0%	+$345	0.35%	40
2023 Q4	$850K	Buy	5,484 +1	+0%	+$146	0.32%	40
2023 Q3	$817K	Sell	5,483 -7	-0.1%	-$1.03K	0.36%	38
2023 Q2	$740K	Buy	5,490 +12	+0.2%	+$1.76K	0.32%	39
2023 Q1	$873K	Sell	5,478 -25	-0.5%	-$3.82K	0.4%	36
2022 Q4	$889K	Buy	5,503 +534	+11%	+$81.9K	0.46%	37
2022 Q3	$667K	Sell	4,969 -50	-1%	-$7.17K	0.39%	39
2022 Q2	$769K	Buy	5,019 +1,168	+30%	+$178K	0.44%	34
2022 Q1	$624K	Hold	3,851	–	–	0.38%	39
2021 Q4	$395K	Hold	3,851	–	–	0.31%	55
2021 Q3	$415K	Hold	3,851	–	–	0.25%	60
2021 Q2	$434K	Hold	3,851	–	–	0.29%	56
2021 Q1	$417K	Hold	3,851	–	–	0.3%	57
2020 Q4	$413K	Hold	3,851	–	–	0.32%	55
2020 Q3	$337K	Sell	3,851 -48	-1%	-$4.52K	0.31%	60
2020 Q2	$382K	Buy	3,899 +48	+1%	+$4.23K	0.37%	51
2020 Q1	$315K	Hold	3,851	–	–	0.34%	63
2019 Q4	$343K	Hold	3,851	–	–	0.34%	71
2019 Q3	$284K	Hold	3,851	–	–	0.3%	79
2019 Q2	$267K	Sell	3,851 -371	-9%	-$29.2K	0.28%	76
2019 Q1	$335K	Hold	4,222	–	–	0.36%	66
2018 Q4	$326K	Buy	+4,222	New	+$371K	0.39%	58

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Hurlow Wealth Management Group's ABBV Position: Q2 2026 in Review

Hurlow Wealth Management Group increased its AbbVie (ABBV) stake by 1.3% in Q2 2026, buying an estimated $11.2K and bringing the position to 4,076 shares worth $1.03M. The position accounts for 0.21% of the portfolio, ranked #41.

Hurlow Wealth Management Group first reported a position in ABBV in Q4 2018 and has held it in 31 quarters since. The position peaked at $1.16M in Q1 2025. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Hurlow Wealth Management Group held 4,076 shares of AbbVie worth $1.03M as of Q2 2026.
Hurlow Wealth Management Group bought 52 AbbVie shares in Q2 2026, an estimated $11.2K.
AbbVie made up 0.21% of Hurlow Wealth Management Group's portfolio in Q2 2026, its #41 holding.
Hurlow Wealth Management Group first reported a position in AbbVie in Q4 2018 and has held it in 31 quarters since.
Hurlow Wealth Management Group's AbbVie position peaked at $1.16M in Q1 2025.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Hurlow Wealth Management Group's 13F filing for Q2 2026, filed 5 Aug 2026.